...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Another possibility?
As at July 31, 2015 the Company had 75,202,620 royalty preferred shares outstanding, all of which were held by Zenith Epigenetics Corp. (“Zenith”). On July 2, 2015, the Company’s articles were amended to make certain changes to the dividend entitlement of holders of royalty preferred shares. Please feel free to pokes holes in anything I've said so far. PVLee
Share
New Message
Please login to post a reply